Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.
暂无分享,去创建一个
H Robert Bergen | Gregory A Poland | H. R. Bergen | G. Poland | I. Ovsyannikova | C. J. Mason | Kenneth L Johnson | Christopher J Mason | Inna G Ovsyannikova | K. L. Johnson
[1] Jennifer N. Sutton,et al. Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members , 2005, Cancer Immunology, Immunotherapy.
[2] Nina Hillen,et al. Contribution of mass spectrometry-based proteomics to immunology , 2006, Expert review of proteomics.
[3] R. Kennedy,et al. T‐Cell epitope discovery for variola and vaccinia viruses , 2007, Reviews in medical virology.
[4] Alexey I Nesvizhskii,et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.
[5] K. Parker,et al. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.
[6] D. Koboldt,et al. The immunogenetics of smallpox vaccination. , 2007, The Journal of infectious diseases.
[7] R. Vierkant,et al. Identification and Characterization of Novel, Naturally Processed Measles Virus Class II HLA-DRB1 Peptides , 2004, Journal of Virology.
[8] R. Jacobson,et al. Heterogeneity in Vaccine Immune Response: The Role of Immunogenetics and the Emerging Field of Vaccinomics , 2007, Clinical pharmacology and therapeutics.
[9] Cécile Gouttefangeas,et al. Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.
[10] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[11] R. Henderson,et al. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. , 1993, Journal of immunology.
[12] Magdalini Moutaftsi,et al. A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.
[13] C. Chu,et al. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. , 1996, The Journal of clinical investigation.
[14] C. Herberts,et al. A microcapillary column switching HPLC-electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules. , 1998, Analytical chemistry.
[15] H. Rammensee,et al. SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.
[16] C. Boog,et al. Mass Tag-Assisted Identification of Naturally Processed HLA Class II-Presented Meningococcal Peptides Recognized by CD4+ T Lymphocytes , 2005, The Journal of Immunology.
[17] F. Ennis,et al. Human Cytotoxic CD4+ T Cells Recognize HLA-DR1-Restricted Epitopes on Vaccinia Virus Proteins A24R and D1R Conserved among Poxviruses1 , 2007, The Journal of Immunology.
[18] Koplan Jp,et al. Smallpox vaccination reactions, prophylaxis, and therapy of complications. , 1975 .
[19] A. Harris,et al. Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia Ankara1 , 2005, The Journal of Immunology.
[20] F. Ennis,et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. , 1997, The Journal of infectious diseases.
[21] F. Falkner,et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.
[22] M. Mann,et al. Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap*S , 2005, Molecular & Cellular Proteomics.
[23] C. Walker,et al. Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans. , 1993, The Journal of general virology.
[24] J. Berzofsky,et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. A. Saper,et al. Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.
[26] Bjoern Peters,et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] Bjoern Peters,et al. HLA-A*0201, HLA-A*1101, and HLA-B*0702 Transgenic Mice Recognize Numerous Poxvirus Determinants from a Wide Variety of Viral Gene Products1 , 2005, The Journal of Immunology.
[28] R. Aebersold,et al. A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.
[29] S. Stevanović,et al. Mass spectrometric identification of an HLA-A*0201 epitope from Plasmodium falciparum MSP-1. , 2008, International immunology.
[30] C. Barnstable,et al. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.
[31] H R Bergen,et al. Mass Spectrometry and Peptide‐based Vaccine Development , 2007, Clinical pharmacology and therapeutics.
[32] M F del Guercio,et al. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. , 1996, Journal of immunology.
[33] D. Fremont,et al. Structural Definition of the H-2Kd Peptide-binding Motif* , 2006, Journal of Biological Chemistry.
[34] Albert J R Heck,et al. Stable Isotope Tagging of Epitopes , 2006, Molecular & Cellular Proteomics.
[35] B. Gückel,et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. , 2001, Cancer research.
[36] O. Lund,et al. novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .
[37] Hans-Georg Rammensee,et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[38] V. Engelhard. The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes. , 2007, International journal of mass spectrometry.
[39] V. Brusic,et al. Long‐term T cell memory to human leucocyte antigen‐A2 supertype epitopes in humans vaccinated against smallpox , 2007, Clinical and experimental immunology.
[40] F. Ennis,et al. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus , 1996, Journal of virology.
[41] S. Ostroff,et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. , 2003, JAMA.
[42] C. Upton,et al. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. , 2007, Vaccine.
[43] Stephen Naylor,et al. The role of mass spectrometry in vaccine development. , 2001, Vaccine.
[44] S Brunak,et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.
[45] G. Poland,et al. Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry. , 2005, Journal of proteome research.
[46] Bjoern Peters,et al. Integrating epitope data into the emerging web of biomedical knowledge resources , 2007, Nature Reviews Immunology.
[47] Bjoern Peters,et al. A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection1 , 2007, The Journal of Immunology.
[48] R. Henderson,et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.
[49] Hans-Georg Rammensee,et al. MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.
[50] H. Rammensee,et al. Towards patient‐specific tumor antigen selection for vaccination , 2002, Immunological reviews.
[51] C. Barnstable,et al. Molecular structure of human histocompatibility antigens: the HLA‐C series , 1977, European journal of immunology.
[52] G. Poland,et al. Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus , 2005, Journal of the American Society for Mass Spectrometry.
[53] C. Melief,et al. Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. , 1998, Journal of immunology.
[54] A Sette,et al. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. , 2001, Human immunology.
[55] C. Melief,et al. Identification of T-cell epitopes for cancer immunotherapy , 2007, Leukemia.
[56] J. Sidney,et al. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.
[57] Lihan K. Yan,et al. Dose-dependent neutralizing-antibody responses to vaccinia. , 2004, The Journal of infectious diseases.